Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial
We have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) vs arsenic trioxide (ATO) + ATRA using an attenuate...
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Veröffentlicht: |
American Society for Haematology
2018
|
| _version_ | 1826277138890752000 |
|---|---|
| author | Russell, N Burnett, A Hills, R Betteridge, S Dennis, M Jovanovic, J Dillon, R Grimwade, D |
| author_facet | Russell, N Burnett, A Hills, R Betteridge, S Dennis, M Jovanovic, J Dillon, R Grimwade, D |
| author_sort | Russell, N |
| collection | OXFORD |
| description | We have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) vs arsenic trioxide (ATO) + ATRA using an attenuated schedule of ATO.1 Here, we present long-term survival results for randomized patients and for 32 patients who received the same schedule of ATO + ATRA after relapsing from the AIDA arm. |
| first_indexed | 2024-03-06T23:24:23Z |
| format | Journal article |
| id | oxford-uuid:69df1d52-d228-4233-a420-07cb0c00833a |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:24:23Z |
| publishDate | 2018 |
| publisher | American Society for Haematology |
| record_format | dspace |
| spelling | oxford-uuid:69df1d52-d228-4233-a420-07cb0c00833a2022-03-26T18:53:50ZAttenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69df1d52-d228-4233-a420-07cb0c00833aSymplectic Elements at OxfordAmerican Society for Haematology2018Russell, NBurnett, AHills, RBetteridge, SDennis, MJovanovic, JDillon, RGrimwade, DWe have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) vs arsenic trioxide (ATO) + ATRA using an attenuated schedule of ATO.1 Here, we present long-term survival results for randomized patients and for 32 patients who received the same schedule of ATO + ATRA after relapsing from the AIDA arm. |
| spellingShingle | Russell, N Burnett, A Hills, R Betteridge, S Dennis, M Jovanovic, J Dillon, R Grimwade, D Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title | Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title_full | Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title_fullStr | Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title_full_unstemmed | Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title_short | Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial |
| title_sort | attenuated arsenic trioxide plus atra therapy for newly diagnosed and relapsed apl long term follow up of the aml17 trial |
| work_keys_str_mv | AT russelln attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT burnetta attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT hillsr attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT betteridges attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT dennism attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT jovanovicj attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT dillonr attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial AT grimwaded attenuatedarsenictrioxideplusatratherapyfornewlydiagnosedandrelapsedapllongtermfollowupoftheaml17trial |